Subscribe To
Amgen confirms us$26bn swoop for horizon therapeutics
US biotechnology giant Amgen, Inc confirmed weekend speculation that it will be acquiring Horizon Therapeutics by formally unveiling a US$26.4bn swo...
December 12, 2022, 7:39 am
Clovis oncology stock slides 10% premarket after company files for bankruptcy
Clovis Oncology Inc. stock CLVS, -9.94% fell 10% in premarket trade Monday, after the biotech filed for...
December 12, 2022, 6:37 am
Amgen set to buy biotech firm horizon at $26 bln valuation - bloomberg news
Amgen Inc is set to buy biotech firm Horizon Therapeutics Plc at a valuation of about $26 billion in wh...
December 12, 2022, 2:50 am
Sana biotechnology highlights hypoimmune allogeneic car t cell programs and in vivo technology platform with six presentations at 2022 ash annual meeting
Transplanted hypoimmune (HIP)-modified allogeneic CD19-targeted CAR T cells control CD19+ tumor cells in fully immunocompetent allogeneic humanized mi...
December 11, 2022, 10:30 pm
Igm biosciences presents data from t cell engager portfolio for hematologic malignancies at 2022 american society of hematology annual meeting
First Preclinical Data for IGM-2644 and IGM-2537 Featured in Poster Presentations MOUNTAIN VIEW, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) — IGM Biosci...
December 11, 2022, 3:00 pm
Amgen nears deal to buy horizon therapeutics
The U.S. biotech company was the last of three suitors standing in an auction for Horizon. A deal would...
December 11, 2022, 2:11 pm
Sanofi says it does not intend to make an offer for horizon, leaving amgen as sole bidder
French health group Sanofi said on Sunday that it no longer intends to make an offer for biotech compan...
December 11, 2022, 1:49 pm
Adaptive biotechnologies highlights new data showcasing the clinical utility of clonoseq® mrd testing in patients with blood cancers at the 64th ash annual meeting
Multiple presentations reinforce clonoSEQ’s ability to provide valuable insights for treatment surveillance and clinical decision-making More than 3...
December 10, 2022, 3:00 pm
Syndax pharmaceuticals: today's best nearby biotech cap-gain prospect
How informed are you about binding interactions of Menin with the mixed lineage leukemia 1 protein for the treatment of acute myeloid leukemia? Neithe...
December 10, 2022, 3:11 am
Illumina: strong eps growth expected, but shares richly valued in a risky space
biotech stocks notched multi-month highs earlier in December but then fell back in a possible bearish f...
December 9, 2022, 6:42 pm
Our 7 top biotech stock picks for 2023
If there's a silver lining regarding the coronavirus pandemic, it's that it demonstrated the importance of the top ...
December 9, 2022, 5:42 pm
Champions oncology to announce second quarter financial results on tuesday, december 13, 2022
HACKENSACK, NJ / ACCESSWIRE / December 9, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled ...
December 9, 2022, 4:30 pm
Why is ambrx (amam) stock up 400% today?
In a topsy-turvy session today, investors may be intrigued by some of the biggest gainers and decliners as most stocks hold around the flat line. Amon...
December 9, 2022, 1:32 pm
Arcellx flies on $325m deal with gilead's kite for multiple myeloma treatment
Arcellx shares soared in early trade after the clinical-stage biotechnology company announced a global strategic collaboration with Gilead Sciences' K...
December 9, 2022, 11:42 am
Is prometheus biosciences a good stock to buy right now?
This biotech stock just jumped over 180% in a single day, and investors want to know if there could be ...
December 9, 2022, 5:32 am
Avid bioservices: production expansion capex and high costs are temporary issues
Avid Bioservices is a CDMO, or a company that manufactures therapies for biotechs and pharmaceuticals. To grow revenues, the company is investing heav...
December 9, 2022, 5:10 am
Replimune announces pricing of public offering
BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of ...
December 9, 2022, 2:04 am
Prometheus biosciences, inc. announces pricing of public upsized $500 million offering of common stock
SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) — Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precisi...
December 9, 2022, 12:39 am
Why shares of alvotech jumped this week
The Icelandic biotech company has a deal to expand the reach of its Humira biosimilar in Eastern Europe...
December 8, 2022, 1:29 pm
Why shares of prometheus biosciences are soaring this week
The clinical-stage biotech that specializes in IBD therapies announced positive news regarding two tria...
December 8, 2022, 12:12 pm